<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218916</url>
  </required_header>
  <id_info>
    <org_study_id>Qilu Hospital</org_study_id>
    <nct_id>NCT04218916</nct_id>
  </id_info>
  <brief_title>Rhodiola Rosea for Coronary Microvascular Disease</brief_title>
  <official_title>The Efficacy and Safety of Rhodiola Rosea in Patients With Coronary Microvascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of rhodiola rosea on coronary flow reserve and symptoms in
      patients with microvascular angina pectoris, and to evaluate adverse drug reactions.
      Long-term clinical follow-up of 1 to 3 years was conducted to evaluate the effect of rhodiola
      rosea on long-term adverse cardiovascular events in patients with coronary microvascular
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Coronary Flow Reserve</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Coronary Microvascular Disease</condition>
  <arm_group>
    <arm_group_label>Rhodiola Rosea Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rhodiola Rosea Capsules</intervention_name>
    <description>0.28g per capsule, 0.56g once (2 capsules), three times a day</description>
    <arm_group_label>Rhodiola Rosea Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 placebo capsules once, three times a day</description>
    <arm_group_label>Placebo Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Repeated chest pain attacks with typical exertional angina pectoris or resting angina
             pectoris attacks;

          2. Coronary normal or stenosis &lt; 20%;

          3. Ischemic depression in ST segment during resting or exercise;

          4. Blood flow reserve (CFR) of the anterior descending coronary artery &lt; 2.0;

          5. Subjects or their guardians agreed to participate in this study.

        Exclusion Criteria:

          1. Previous myocardial infarction or PCI or CABG treatment;

          2. A history of heart failure or LVEF &lt; 50%;

          3. Severe arrhythmia;

          4. Myocarditis, Pericardium Disease, Valvular Disease, or Cardiomyopathy;

          5. A history of stroke within half a year;

          6. Diabetes difficult to control;

          7. Refractory hypertension or hypertension accompanied by left ventricular wall thickness
             &gt; 12 mm;

          8. Familial hypercholesterolemia;

          9. Takayasu arteritis, Kawasaki disease or coronary artery malformation;

         10. Pregnant or nursing, or having the intention to give birth within one year;

         11. Hepatic or renal dysfunction;

         12. Other diseases which may cause serious risks to patients;

         13. Requiring warfarin anticoagulant therapy; Taking potassium channel opener, CCB, ACEI
             drugs or traditional Chinese medicines;

         14. Allergic to contrast agents or blood products;

         15. Patients who participated in clinical research of other drugs within 3 months before
             being selected.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Pan-Pan Hao</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Microvascular Angina</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

